Sumitomo Chemical Co., Ltd.

Sumitomo Chemical Co., Ltd.

3.28
EUR
-0.08
(-2.26%)
4.49BMarket Cap
Nov 02Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
1,372.73
1,454.14
1,286.04
1,185.83
1,339.68
1,418.06
1,361.34
1,398.77
1,691.35
1,770.84
1,496.25
1,593.17
1,419.72
- -
Basic EPS, GAAP
22.62
31.93
49.84
46.81
81.81
72.17
18.91
28.16
99.16
4.27
-190.69
23.59
37.16
- -
Free Cash Flow per Basic Share
118.91
159.6
159.81
113.61
179.35
127.3
64.84
229.03
105.03
-19.55
-124.86
142.45
143.13
- -
Dividend per Share
6
9.01
11.01
13
17
23
22
12
19
25.98
12.01
6.03
12
- -
Book Value per Share
393.58
484.17
457.06
497.27
567.04
610.82
565.13
623.39
745.03
716.16
590.33
550.37
610.78
- -
Tangible Book Value per Share
274.05
359.3
343.21
281.07
349.63
400.73
157.75
213.31
307.33
305.94
262.28
246.63
307.37
- -
Basic Weighted Avg Shares
1,635
1,634
1,634
1,635
1,635
1,635
1,635
1,635
1,635
1,635
1,635
1,636
1,640
1,645
Sales/Revenue/Turnover
2,243,794
2,376,697
2,101,764
1,939,069
2,190,509
2,318,572
2,225,804
2,286,978
2,765,321
2,895,283
2,446,893
2,606,281
2,328,515
- -
Operating Margin (%)
4.49
5.36
7.82
4.34
8.93
6.29
5.76
6.54
6.25
-0.84
-17.63
6.61
8.38
- -
Depreciation Expense
115,734
119,177
116,602
110,308
107,103
112,495
131,741
136,017
156,667
167,957
157,522
131,597
121,069
- -
Net Income, GAAP
36,977
52,192
81,451
76,540
133,768
117,992
30,926
46,043
162,130
6,987
-311,838
38,591
60,947
- -
Effective Tax Rate (%)
36.24
39.07
28.67
10.82
26.02
19.06
58.31
50.6
25.76
20,387.88
- -
26.52
0.57
- -
Profit Margin (%)
1.65
2.2
3.88
3.95
6.11
5.09
1.39
2.01
5.86
0.24
-12.74
1.48
2.62
- -
Working Capital
293,313
391,061
251,720
184,648
225,868
286,089
148,578
493,779
639,151
484,517
232,395
544,387
506,364
- -
LT Debt
731,591
693,632
604,270
573,476
552,971
582,965
838,139
1,100,677
1,089,190
1,064,463
977,581
1,033,236
910,033
- -
Total Equity
934,506
1,118,216
1,029,079
1,115,903
1,252,214
1,351,886
1,392,592
1,482,119
1,701,977
1,489,189
1,164,366
1,074,415
1,236,673
- -
Return on Invested Capital (%)
3.35
3.75
5.84
5.74
8.96
6.82
2.32
2.42
5.37
207.48
- -
5.55
6.33
- -
Return on Capital (%)
1.42
2.02
2.98
2.96
5.15
4.32
0.65
1.21
5.27
-265.78
- -
5.76
2.94
- -
Return on Common Equity (%)
6.49
7.28
10.59
9.82
15.38
12.25
3.22
4.74
14.49
0.58
-29.19
4.14
6.38
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
197,406
241,422
- -
LT Borrowings
994,262
910,033
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,637
1,651
1,651
Market Capitalization
755,760
823,932
852,046

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
1,577,505
1,507,710
- -
Cash, Cash Equivalents & STI
216,363
256,140
- -
Accounts Receivable, Net
581,477
608,670
- -
Inventories
643,721
595,471
- -
Total Current Liabilities
932,628
1,001,346
- -
Payables & Accruals
- -
- -
- -
ST Debt
197,406
241,422
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.6%
-2.42%
15.1%
Free Cash Flow
35.69%
30.55%
0.74%
Net Income, GAAP
-442.91%
-892.23%
57.93%
Sales/Revenue/Turnover
1.58%
1.2%
-10.66%
Total Cash Common Dividend
12.55%
18.21%
99.47%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2,606,281
2026
- -
- -
- -
- -
2,328,515
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
23.59
2026
- -
- -
- -
- -
37.16
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
6.03
2026
- -
- -
- -
- -
12
2027
- -
- -
- -
- -
- -

Company Description

CEO
Nobuaki Mito
Full Time Employees
27,491
Sector
Process industries
Industry
Chemicals: specialty
Address
Tokyo Sumitomo Twin Building (East) Tokyo TY Japan 103-6020
IPO Date
May 16, 1949
Business
Sumitomo Chemical Company, Limited (4005.T) manufactures and markets a broad portfolio of chemicals and related products through five principal segments: Agro & Life Solutions; ICT & Mobility Solutions; Advanced Medical Solutions; Essential & Green Materials; and Sumitomo Pharma. The Agro & Life Solutions segment provides crop protection chemicals including pesticides and insecticides, fertilizers, agricultural materials, household insecticides, products for infectious disease control, and feed additives; the ICT & Mobility Solutions segment offers optical products, color filters, semiconductor processing materials, compound semiconductor materials, touch screen sensor panels, and battery components; the Advanced Medical Solutions segment develops ethical pharmaceuticals, radiopharmaceuticals, and radiation therapy equipment; the Essential & Green Materials segment produces synthetic resins, raw materials for synthetic fibers, industrial chemicals, methacrylates, processed synthetic resin products, aluminum and alumina, synthetic rubber, engineering plastics, dyes, additives, and battery parts; and Sumitomo Pharma focuses on pharmaceuticals including regenerative medicine initiatives. The company, founded in 1913 and headquartered in Tokyo, Japan, maintains global operations with manufacturing facilities, R&D centers, and sales networks across Asia, North America, Europe, Latin America, and other regions, serving industries such as agriculture, healthcare, electronics, energy, and automotive. Recent strategic developments include the November 2025 agreement to acquire 100% of Asia Union Electronic Chemical Corporation, a Taiwanese semiconductor process chemicals firm, to bolster its global manufacturing footprint with new bases in Taiwan and the United States; the February 2025 acquisition of the LCP neat resin business intangible asset from Syensqo SA/NV to expand product and technology offerings; the full acquisition of Philagro Holding S.A. in France and Kenogard S.A. in Spain and Portugal to strengthen European crop protection sales; and an increase in ownership of a regenerative medicine CDMO to 66.6% effective October 2024, alongside plans for a new joint venture with Sumitomo Pharma.

Company News

  • Sumitomo Chemical Company, Limited (SOMMY) Q1 2026 Earnings Call Transcript

  • Comparing Tosoh (OTCMKTS:TOSCF) and Sumitomo Chemcl (OTCMKTS:SOMMY)

  • Short Interest in Sumitomo Chemcl (OTCMKTS:SOMMY) Grows By 197.1%

  • Sumitomo Chemcl (OTCMKTS:SOMMY) and Valhi (NYSE:VHI) Critical Comparison

  • Sumitomo Chemical Company, Limited (SOMMY) Q3 2025 Earnings Call Transcript

  • Sumitomo Chemcl (OTCMKTS:SOMMY) Shares Gap Up – Still a Buy?

  • Head-To-Head Review: Sumitomo Chemcl (OTCMKTS:SOMMY) versus Innospec (NASDAQ:IOSP)

  • Sumitomo Chemical Company, Limited (SOMMY) Q3 2024 Earnings Call Transcript

  • Samsung Electro-Mechanics Signs MOU with Sumitomo Chemical Group to Establish a Joint Venture for 'Glass Core' Used in Package Substrates

  • Sumitomo Chemical Company, Limited (SOMMY) Q2 2026 Earnings Call Transcript

  • Analyzing SUMITOMO CHEMCL (OTCMKTS:SOMMY) and Gulf Resources (NASDAQ:GURE)

  • Sumitomo Chemical Company, Limited - Special Call

  • Sumitomo Chemical Company, Limited (SOMMY) Q1 2025 Earnings Call Transcript

  • Chloroethane Global Market Insights 2025, Analysis and Forecast to 2030, with Profiles of Westlake, Sumitomo Chemical, and Lanxess

  • Middle East and Africa Electric Vehicle Battery Separator Market Forecast Report 2025-2030, with Key Player Profiles for Entek, Toray, Sinoma, UBE, Celgard, Sumitomo Chemical & Abu Dhabi Polymers

  • Sumitomo Chemical Company, Limited (SOMMY) Q4 2024 Earnings Call Transcript

  • Sumitomo Chemical Company, Limited (SOMMY) Q3 2025 Earnings Call Transcript

  • Sumitomo Chemical Company, Limited (SOMMY) Q2 2024 Earnings Call Transcript

  • Aluminum Hydroxide Industry Business Report 2023-2030 with Focus on 40+ Select Players Including Aluminum Corp of China, J.M. Huber, Nabaltec, Showa Denko, Sumitomo Chemical, & The R.J.

  • Sumitomo Chemical Company, Limited (SOMMY) Q1 2025 Earnings Call Transcript